Imatinib Treatment for Gastrointestinal Stromal Tumours
Author Information
Author(s): Bümming P, Andersson J, Meis-Kindblom J M, Klingenstierna H, Engström K, Stierner U, Wängberg B, Jansson S, Ahlman H, Kindblom L-G, Nilsson B
Primary Institution: Sahlgrenska University Hospital
Hypothesis
Can imatinib effectively treat high-risk and malignant gastrointestinal stromal tumours (GIST)?
Conclusion
Imatinib treatment can significantly reduce tumour size in patients with malignant GIST, making surgical resection possible.
Supporting Evidence
- Eight of 11 patients receiving palliative treatment had a partial response to imatinib.
- None of the patients developed serious side effects from imatinib.
- Imatinib treatment allowed for surgical resection of previously unresectable tumours.
Takeaway
This study shows that a medicine called imatinib can help shrink certain stomach tumors, making it easier for doctors to remove them.
Methodology
Patients with high-risk or malignant GIST were treated with imatinib in neoadjuvant, adjuvant, and palliative settings, and their responses were evaluated using imaging techniques.
Limitations
The study is limited by its small sample size and lack of a control group.
Participant Demographics
Patients included 10 males and 7 females, with ages ranging from 10 to 74 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website